Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from PAVmed ( (PAVM) ) is now available.
On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.
The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
PAVmed’s overall stock score reflects a mixed outlook. Financial challenges and bearish technical signals weigh heavily, while strategic initiatives and a low P/E ratio provide some optimism. The company’s ability to navigate its operational issues and leverage strategic opportunities will be crucial to future performance.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
Average Trading Volume: 162,344
Technical Sentiment Signal: Sell
Current Market Cap: $9.87M
For detailed information about PAVM stock, go to TipRanks’ Stock Analysis page.